Additionally, most cancers (except for glioblastoma) retain at least one wild-type PTEN allele [173,174]; thus, developing E3-targeting therapies to stabilize the wild-type PTEN protein will be of remarkable value. The gene discussed is PTEN; the disease is glioblastoma.